Supporting one of the world’s largest pharmaceutical companies, 2 Dedicated Research Sites of FutureMeds Poland enrolled 460 participants in a randomised, placebo-controlled, Phase III multicenter vaccine trial.
The sponsor’s ongoing Phase III study aims to test the efficacy, safety, tolerability and immunogenicity of a new vaccine for Lyme disease. They hope to take a step closer to potentially bringing a new vaccine to adults and children who would benefit from it.
The trial that aims to enrol approximately 6,000 participants 5 years of age and older within North America and Europe is conducted across up to 50 sites located in areas where Lyme disease is highly endemic; Finland, Germany, the Netherlands, Poland, Sweden and the United States.
Lyme disease is the most prevalent vector-borne disease in humans across the northern hemisphere’s temperate regions, with hundreds of thousands of people in North America and Eurasia affected annually. Lyme disease can be contracted at any age; however, incidence peaks in 5 to 15 years old children and over 50 years old adults.
In the US, an estimated 476,000 patients were diagnosed and treated annually from 2010 to 2018. In Europe, approximately 65,000 to 85,000 cases have been reported per year. However, because Lyme disease is often undiagnosed and there is inconsistent case reporting, the officials can largely underestimate this number.
FutureMeds’ patient-focused approach ensures an agile response to trial recruitment requirements and challenges
By instilling a patient-first approach, improving the patient experience over years of focused effort, and leveraging multichannel recruitment activities, FutureMeds Poland has rapidly increased recruitment while maintaining patient adherence and safety for this study.
“I am very proud of the effective collaboration between our CSR, patient engagement and Dedicated Research Sites teams in Krakow and Wroclaw. As a result of their outstanding work, FutureMeds Poland delivered around 7.5% of the target study population within 10 weeks and became the top recruiter in the region.”
- Dr Piotr Rozpondek, Managing Director of FutureMeds Poland
By leveraging effective recruitment methods, utilising FutureMeds patient database and engaging doctors through the CRS team, and thanks to patient referrals and word of mouth, FutureMeds Dedicated Research Sites enrolled 460 participants; FutureMeds Krakow enrolled 287 participants. FutureMeds Wroclaw enrolled 173.
“Our sites delivered a fantastic result. Yet our patient engagement, CRS team and recruitment partners can only take some of the credit. Many patients recommended their relatives for this trial thanks to the excellent work of FutureMeds’ dedicated research doctors, nurses and administrative staff. We will continue our work and aim to make FutureMeds the first choice for patients looking for new therapeutic options.”
- Arkadiusz Kasperski, Head of Patient Engagement at FutureMeds
The sponsor’s multiyear Lyme disease study is ongoing, and our Dedicated Research Site teams will continue to deliver their best to maximise retention during the trial.
At FutureMeds, we are on a mission to forge strong and lasting ties with healthcare providers and patients alike to help them access the best available treatment options.
FutureMeds is a fast-growing independent Dedicated Research Site Network supporting pharmaceutical companies, Sponsors and CROs and contributing to research to find effective treatments and medications for all patients who need them.
FutureMeds’ Dedicated Research Site teams strive to accelerate study timelines, streamline processes, lower costs and improve data quality to help accelerate patient access to new treatments.
Through acquisitions and a strategic focus on patient experience, FutureMeds has developed qualified patient pools across Europe that enables faster patient enrollment and strong retention and help generate more accurate results.
Follow us on LinkedIn
Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.